Multiple endocrine neoplasia 1(MEN1)syndrome,a disease arising from a genetic predisposition to tumor development caused by MEN1 loss-of-function mutations,is characterized by the combined occurrence of neuroendocrine...Multiple endocrine neoplasia 1(MEN1)syndrome,a disease arising from a genetic predisposition to tumor development caused by MEN1 loss-of-function mutations,is characterized by the combined occurrence of neuroendocrine tumors in multiple human organs.With advances in diagnostic technologies and improvements in living standards.展开更多
The overall survival rate of pancreatic ductal adenocarcinoma(PDAC)is the worst among all cancers,which is mainly due to the fact that most patients are in the late tumor stage when diagnosed,lacking effective treatme...The overall survival rate of pancreatic ductal adenocarcinoma(PDAC)is the worst among all cancers,which is mainly due to the fact that most patients are in the late tumor stage when diagnosed,lacking effective treatment options.Although targeted therapy has shown some prospects in PDAC,its efficacy is limited to patients with specific gene mutation or target gene expression.A large number of patients have no other treatment options except chemotherapy.However,the high drug resistance rate of chemotherapy for PDAC severely limits the improvement of curative effect.Therefore,determining the key factors that lead to drug resistance in PDAC is crucial to improve the prognosis of patients.Multifunctional oncoprotein Y-box binding protein 1(YBX1)may be one of such potential targets.Studies have confirmed that YBX1 is associated with the inherent behavior of a variety of cancers,such as proliferation,invasion,metastasis,and cancer cell stemness.Herein,we integrated and analyzed the resistance mechanism of YBX1 in anti-tumor therapy,and discussed its potential as a therapeutic target to reverse the chemotherapy resistance of PDAC.展开更多
基金jointly supported by the National Natural Science Foundation of China(Grant No.U21A20374),National Natural Science Foundation of China(Grant Nos.82141129 and 82141104)Shanghai Municipal Science and Technology Major Project(Grant No.21JC1401500)+4 种基金Scientific Innovation Project of Shanghai Education Committee(Grant No.2019-01-0700-07-E00057)Clinical Research Plan of Shanghai Hospital Development Center(Grant No.SHDC2020CR1006A)Xuhui District Artificial Intelligence Medical Hospital Cooperation Project(Grant No.2021-011)Shanghai Municipal Science and Technology Commission(Grant No.19QA1402100)Shanghai Pujiang Program(Grant No.22PJ1401800).
文摘Multiple endocrine neoplasia 1(MEN1)syndrome,a disease arising from a genetic predisposition to tumor development caused by MEN1 loss-of-function mutations,is characterized by the combined occurrence of neuroendocrine tumors in multiple human organs.With advances in diagnostic technologies and improvements in living standards.
基金supported by the Excellence project of Shanghai Municipal Health Commission(20224Z0006)Sailing Project of Science and Technology Commission of Shanghai Municipality(22YF1409000)+3 种基金Eyas Project of Shanghai Anticancer Association(SACA-CY21C11)Shanghai Municipal Science and Technology Major Project(21JC1401500)Scientific Innovation Project of Shanghai Education Committee(2019–01-07–00-07-E00057)Clinical Research Plan of Shanghai Hospital Development Center(SHDC-2020CR1006A).
文摘The overall survival rate of pancreatic ductal adenocarcinoma(PDAC)is the worst among all cancers,which is mainly due to the fact that most patients are in the late tumor stage when diagnosed,lacking effective treatment options.Although targeted therapy has shown some prospects in PDAC,its efficacy is limited to patients with specific gene mutation or target gene expression.A large number of patients have no other treatment options except chemotherapy.However,the high drug resistance rate of chemotherapy for PDAC severely limits the improvement of curative effect.Therefore,determining the key factors that lead to drug resistance in PDAC is crucial to improve the prognosis of patients.Multifunctional oncoprotein Y-box binding protein 1(YBX1)may be one of such potential targets.Studies have confirmed that YBX1 is associated with the inherent behavior of a variety of cancers,such as proliferation,invasion,metastasis,and cancer cell stemness.Herein,we integrated and analyzed the resistance mechanism of YBX1 in anti-tumor therapy,and discussed its potential as a therapeutic target to reverse the chemotherapy resistance of PDAC.
